GOVX Logo

GeoVax Labs, Inc. (GOVX) 

NASDAQ
Market Cap
$22.08M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
347 of 958
Rank in Industry
210 of 549

Largest Insider Buys in Sector

GOVX Stock Price History Chart

GOVX Stock Performance

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership …

Insider Activity of GeoVax Labs, Inc.

Over the last 12 months, insiders at GeoVax Labs, Inc. have bought $40,921 and sold $0 worth of GeoVax Labs, Inc. stock.

On average, over the past 5 years, insiders at GeoVax Labs, Inc. have bought $46,191 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: DODD DAVID A (President, CEO) — $35,381. Reynolds Mark (CFO) — $5,540.

The last purchase of 8,000 shares for transaction amount of $15,600 was made by DODD DAVID A (President, CEO) on 2024‑08‑09.

List of Insider Buy and Sell Transactions, GeoVax Labs, Inc.

2024-08-09PurchasePresident, CEO
8,000
0.1589%
$1.95$15,600+31.02%
2024-02-22PurchasePresident, CEO
8,209
0.431%
$2.27$18,663-7.08%
2024-02-21PurchasePresident, CEO
520
0.0257%
$2.15$1,118-7.27%
2024-02-07PurchaseCFO
2,000
0.0718%
$2.77$5,540-18.41%
2023-12-22PurchaseChief Medical Officer
6,944
0.0257%
$0.36$2,500+458.02%
2023-09-25PurchaseChief Medical Officer
9,653
0.0371%
$0.52$5,020+218.67%
2023-08-25PurchasePresident, CEO
35,087
0.1351%
$0.57$20,000+161.61%
2023-08-18PurchaseCFO
10,000
0.038%
$0.52$5,179+171.84%
2023-04-24PurchasePresident, CEO
32,000
0.122%
$0.64$20,445-10.61%
2023-04-20PurchaseCFO
8,000
0.0297%
$0.63$5,040-11.90%
2022-09-21Purchasedirector
10,000
0.043%
$1.10$11,000-39.22%
2022-07-01PurchaseVP, Business Development
1,000
0.0043%
$0.82$820-6.48%
2022-06-27PurchaseChief Medical Officer
4,464
0.0367%
$1.12$5,000-28.60%
2022-06-21Purchase
10,000
0.0761%
$1.21$12,100-38.32%
2022-05-05PurchaseChief Medical Officer
9,722
0.0758%
$0.72$7,000+11.57%
2022-05-04PurchaseChief Medical Officer
4,999
0.0362%
$0.71$3,549+5.19%
2011-12-30PurchaseCSO Emeritus
149,254
<0.0001%
$0.67$100,000
2011-12-30PurchasePresident, CEO
112,000
<0.0001%
$0.67$75,040
2011-12-30PurchaseCFO
15,000
<0.0001%
$0.67$10,050
2010-07-02PurchaseCFO
1,000
<0.0001%
$2.50$2,500

Insider Historical Profitability

<0.0001%
DODD DAVID APresident, CEO
26661
0.2825%
$2.3490<0.0001%
Reynolds MarkCFO
7213
0.0764%
$2.3490<0.0001%
ROBINSON HARRIET LCSO Emeritus
1201226
12.7302%
$2.3458
Tsolinas Peter Mdirector
431734
4.5754%
$2.3410
CHASE RANDAL Ddirector
36613
0.388%
$2.3420<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.